Blood Cancer Journal

Blood Cancer Journal

血癌杂志

  • 1区 中科院分区
  • Q1 JCR分区

期刊简介

《Blood Cancer Journal》是由Springer Nature出版社于2011年创办的英文国际期刊(ISSN: 2044-5385,E-ISSN: 2044-5385),该期刊长期致力于血液学领域的创新研究,主要研究方向为ONCOLOGY。作为SCIE收录期刊(JCR分区 Q1,中科院 1区),本刊采用OA开放获取模式(OA占比1%),以发表血液学领域等方向的原创性研究为核心(研究类文章占比87.88%%)。凭借严格的同行评审与高效编辑流程,期刊年载文量精选控制在99篇,确保学术质量与前沿性。成果覆盖Web of Science、Scopus等国际权威数据库,为学者提供推动医学领域高水平交流平台。

投稿咨询

投稿提示

Blood Cancer Journal审稿周期约为 12周,或约稿 。该刊近年未被列入国际预警名单,年发文量约99篇,录用竞争适中,主题需确保紧密契合医学前沿。投稿策略提示:避开学术会议旺季投稿以缩短周期,语言建议专业润色提升可读性。

  • 医学 大类学科
  • English 出版语言
  • 是否预警
  • SCIE 期刊收录
  • 99 发文量

中科院分区

中科院 SCI 期刊分区 2023年12月升级版

Top期刊 综述期刊 大类学科 小类学科
医学
1区
HEMATOLOGY 血液学 ONCOLOGY 肿瘤学
1区 1区

中科院 SCI 期刊分区 2022年12月升级版

Top期刊 综述期刊 大类学科 小类学科
医学
1区
HEMATOLOGY 血液学 ONCOLOGY 肿瘤学
2区 2区

JCR分区

按JIF指标学科分区 收录子集 分区 排名 百分位
学科:HEMATOLOGY SCIE Q1 5 / 97

95.4%

学科:ONCOLOGY SCIE Q1 18 / 322

94.6%

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:HEMATOLOGY SCIE Q1 8 / 97

92.27%

学科:ONCOLOGY SCIE Q1 28 / 322

91.46%

CiteScore

CiteScore SJR SNIP CiteScore 排名
CiteScore:16.7 SJR:3.974 SNIP:2.487
学科类别 分区 排名 百分位
大类:Medicine 小类:Hematology Q1 8 / 137

94%

大类:Medicine 小类:Oncology Q1 30 / 404

92%

期刊发文

  • Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy?

    Author: Liu, Sining; Zhang, Xinyue; Dai, Haiping; Cui, Wei; Yin, Jia; Li, Zheng; Yang, Xiao; Yang, Chunxiu; Xue, Shengli; Qiu, Huiying; Miao, Miao; Chen, Suning; Jin, Zhengming; Fu, Chengcheng; Li, Caixia; Sun, Aining; Han, Yue; Wang, Ying; Yu, Lei; Wu, Depei; Cui, Qingya; Tang, Xiaowen

    Journal: BLOOD CANCER JOURNAL. 2023; Vol. 13, Issue 1, pp. -. DOI: 10.1038/s41408-023-00819-5

  • Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies

    Author: Zhang, Yinqiang; Li, Chenggong; Du, Mengyi; Jiang, Huiwen; Luo, Wenjing; Tang, Lu; Kang, Yun; Xu, Jia; Wu, Zhuolin; Wang, Xindi; Huang, Zhongpei; Zhang, Yanlei; Wu, Di; Chang, Alex H. H.; Hu, Yu; Mei, Heng

    Journal: BLOOD CANCER JOURNAL. 2023; Vol. 13, Issue 1, pp. -. DOI: 10.1038/s41408-023-00822-w

  • High expression of PTPN21 in B-cell non-Hodgkin's gastric lymphoma, a positive mediator of STAT5 activity.

    Author: Plani-Lam JH, Chow TC, Fan YH, Garcia-Bloj B, Cheng L, Jin DY, Hancock W, Fanayan S, Ingley E, Song YQ.

    Journal: Blood Cancer J. 2016 Jan 15;6:e388. doi: 10.1038/bcj.2015.107. No abstract available.

  • Efficacy, safety and pharmacokinetics of clofarabine in Chinese pediatric patients with refractory or relapsed acute lymphoblastic leukemia: a phase II, multi-center study.

    Author: Lu A, Fang Y, Du X, Li Y, Cai Z, Yu K, Zhao L, Wang B, Wu J, Cheng Y, Zuo Y, Jia Y, Tan F, Ding L, Lu J, Zhang L, Huang X.

    Journal: Blood Cancer J. 2016 Feb 26;6:e400. doi: 10.1038/bcj.2016.8. No abstract available.

  • The microenvironment of classical Hodgkin lymphoma: heterogeneity by Epstein-Barr virus presence and location within the tumor.

    Author: Wu R, Sattarzadeh A, Rutgers B, Diepstra A, van den Berg A, Visser L.

    Journal: Blood Cancer J. 2016 May 6;6:e417. doi: 10.1038/bcj.2016.26. No abstract available.

  • Differential clinical and prognostic impact of myeloid sarcoma vs medullary myeloid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy.

    Author: Chen Z, Wang W, Cortes JE, Liu E, Miranda RN, Zhao C, Yuan J, Lu X, Yang W, Ameri MD, Kantarjian HM, Medeiros LJ, Hu S.

    Journal: Blood Cancer J. 2016 May 6;6:e418. doi: 10.1038/bcj.2016.27. No abstract available.

  • Next-generation sequencing with a myeloid gene panel in core-binding factor AML showed KIT activation loop and TET2 mutations predictive of outcome.

    Author: Cher CY, Leung GM, Au CH, Chan TL, Ma ES, Sim JP, Gill H, Lie AK, Liang R, Wong KF, Siu LL, Tsui CS, So CC, Wong HW, Yip SF, Lee HK, Liu HS, Lau JS, Luk TH, Lau CK, Lin SY, Kwong YL, Leung AY.

    Journal: Blood Cancer J. 2016 Jul 8;6(7):e442. doi: 10.1038/bcj.2016.51.

  • Reprogramming of Notch1-induced acute lymphoblastic leukemia cells into pluripotent stem cells in mice.

    Author: Zhang H, Cheng H, Wang Y, Zheng Y, Liu Y, Liu K, Xu J, Hao S, Yuan W, Zhao T, Cheng T.

    Journal: Blood Cancer J. 2016 Jul 8;6(7):e444. doi: 10.1038/bcj.2016.57. No abstract available.